Key regions: United Kingdom, Germany, France, South Korea, Italy
Uruguay, a small country in South America, has been making strides in the COVID-19 vaccination efforts.
Customer preferences: Uruguayans have shown a high level of trust in vaccines and have been generally receptive to getting vaccinated. This has been reflected in the high vaccination rates in the country. Additionally, the government has been proactive in securing vaccine supplies and ensuring equitable access to vaccines for all citizens.
Trends in the market: The COVID-19 vaccine market in Uruguay has been marked by the dominance of Sinovac, a Chinese vaccine manufacturer. Sinovac's vaccine has been the most widely used in the country, with a majority of the population receiving it. However, there has been a recent increase in the use of the Pfizer-BioNTech vaccine, which has been shown to be highly effective against the Delta variant of the virus. This shift towards the Pfizer-BioNTech vaccine is in line with global trends, as countries increasingly prioritize the use of mRNA vaccines over traditional inactivated virus vaccines.
Local special circumstances: Uruguay has a relatively small population, which has made it easier for the government to secure vaccine supplies and distribute them efficiently. Additionally, the country has a strong public healthcare system, which has been instrumental in the vaccination efforts. The government has also implemented a successful communication campaign to encourage vaccine uptake and combat vaccine hesitancy.
Underlying macroeconomic factors: Uruguay has a relatively high GDP per capita compared to other countries in the region, which has allowed the government to invest in vaccine procurement and distribution. Additionally, the country has a stable political environment and a history of strong social welfare policies, which has helped to build trust in the government's handling of the pandemic. However, the country has also faced economic challenges in recent years, which may impact the sustainability of the vaccination efforts in the long term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
